Jahn Ellen, Sausele Tanja
Med Monatsschr Pharm. 2009 Nov;32(11):402-7.
The GLP-1-receptor-agonist liraglutide (Victoza) has been approved for the treatment of diabetes mellitus type 2 in Europe. Liraglutide is the first human GLP-1 analogue which is applied once a day. Efficacy and safety of liraglutide were investigated in the broad LEAD-study-programme in comparison with placebo and other common therapeutics for the treatment of diabetes mellitus type 2. Liraglutide has been approved for the combination with metformin and/or a sulfonylurea or with metformin and a thiazolidinedione, if treatment with one or a combination of these drugs is not sufficient for an adequate blood glucose control.
胰高血糖素样肽-1受体激动剂利拉鲁肽（维达列汀）已在欧洲获批用于治疗2型糖尿病。利拉鲁肽是首个每日给药一次的人胰高血糖素样肽-1类似物。在广泛的LEAD研究项目中，对利拉鲁肽与安慰剂及其他治疗2型糖尿病的常用疗法进行了疗效和安全性对比研究。如果使用这些药物中的一种或几种联合治疗仍不足以充分控制血糖，则利拉鲁肽已获批可与二甲双胍和/或磺脲类药物联合使用，或与二甲双胍和噻唑烷二酮类药物联合使用。
